Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein (S1,C-mFC Tag)

Recombinant 2019 nCoV (SARS2 coronavirus) Antigens reagents

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Source (Expression Host)	Tag	Bioactivity validation	Order
GMP-V-2019nCoV-N002	Recombinant 2019-nCoV(SARS-CoV-2) Nucleocapsid Protein (N protein,N-His tag)	E.coli	N-His	Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays
GMP-V-2019nCoV-SRBD001	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein (RBD, C-His Tag)	Mamamlian (human cell)	C-His	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays Validated in Spike (RBD)-hACE2 competition assay.
GMP-V-2019nCoV-SRBD002	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein (RBD, C-mFC Tag)	Mamamlian (human cell)	C-mFc	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays Validated in Spike (RBD)-hACE2 competition assay.
GMP-V-2019nCoV-S1001	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein (S1, His Tag)	Baculovirus-Insect Cells	C-His
GMP-V-2019nCoV-S1S2001	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein (S1+S2 ECD, His tag)	Baculovirus-Insect Cells	C-His	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays;
GMP-V-2019nCoV-E001	Recombinant 2019-nCoV(SARS-CoV-2) Envelope Protein (E protein,His Tag)	E.coli	N-His	Enzyme activity validation in biochemical assay
GMP-H-ACE2001	Recombinant human soluble ACE2 protein (soluble hACE2,extracellular hACE2,C-His)	Mamamlian (human cell)	C-His	Spike(S-RBD or S1S2ECD) protein binding. Validated in Spike (RBD)-hACE2 competition assay.
GMP-H-ACE2002	Recombinant human soluble ACE2 protein (soluble hACE2,extracellular hACE2, C-FC)	Mamamlian (human cell)	C-Fc	Spike(S-RBD or S1S2ECD) protein binding. Validated in Spike (RBD)-hACE2 competition assay.
GMP-V-2019nCoV-Mpro001	Recombinant 2019-nCoV(SARS-CoV-2) Main Proteinase (Mpro,3CLpro, His Tag)	E.coli	N-His	Enzyme activity validation in biochemical assay
GMP-V-2019nCoV-PLpro001	Recombinant 2019-nCoV(SARS-CoV-2) papain-like proteinase (PLpro, Nsp3, His Tag)	E.coli	N-His	In Testing
GMP-V-2019nCoV-RdRP001	Recombinant 2019-nCoV(SARS-CoV-2) RNA-directed RNA polymerase(RdRP, Nsp12, His Tag)	E.coli	C-His	In Testing
GMP-V-2019nCoV-Nsp3X-01	Recombinant 2019-nCoV(SARS-CoV-2)Nsp3-X domain(Macro domain, His tag)	E.coli	N-His	In Testing
GMP-V-2019nCoV-Nsp10-01	Recombinant 2019-nCoV(SARS-CoV-2) nsp10 (nsp10-CysHis,GFL protein,His Tag)	E.coli	N-His	In Testing
GMP-V-2019nCoV-Nsp16-01	Recombinant 2019-nCoV(SARS-CoV-2) nsp16 (nsp16-OMT,2'-o-MT,His Tag)	E.coli	N-His	In Testing

2019 nCoV (SARS2 coronavirus) Antibodies for COVID-19

Cat No.	Products Name	Host specics	Source (Expression Host)	Bioactivity validation	Order
GMP-V-2019nCoV-NAb001	Anti-2019-nCoV NP human monoclonal antibody	human IgG	Mammalian (human cell)	N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb002 , GMP-V-2019nCoV-NAb003 , GMP-V-2019nCoV-NAb004.
GMP-V-2019nCoV-NAb002	Anti-2019-nCoV NP human scFv-Fc antibody	Scfv	Mammalian (human cell)	N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb003 , GMP-V-2019nCoV-NAb004.
GMP-V-2019nCoV-NAb003	Anti-2019-nCoV NP mouse monoclonal antibody(mAb)	Mouse IgG	Hybridoma	N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb002, GMP-V-2019nCoV-NAb004.
GMP-V-2019nCoV-NAb004	Anti-2019-nCoV NP mouse monoclonal antibody(mAb)	Mouse IgG	Hybridoma	N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb002 , GMP-V-2019nCoV-NAb003.
GMP-V-2019nCoV-S1Ab001	Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody	human IgG	Mammalian (human cell)	S-RBD protein binding, ELISA validated
GMP-V-2019nCoV-S1Ab002	Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody	human IgG	Mammalian (human cell)	S-RBD protein binding, ELISA validated, Western Blot validated
GMP-V-2019nCoV-S1Ab003	Anti-2019-nCoV Spike (S1 protein) mouse monoclonal antibody (mAb)	Mouse IgG	Hybridoma	S-RBD protein binding, ELISA validated
GMP-V-2019nCoV-S1Ab004	Anti-2019-nCoV Spike (S1 protein) mouse monoclonal antibody (mAb)	Mouse IgG	Hybridoma	S-RBD protein binding, ELISA validated

GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus):
https://www.genemedi.net/i/2019-ncov-gene-vectors

About SARS-CoV-2 (2019nCoV, novel Coronavirus) Spike protein, S1 Protein, Spike S1-NTD, Spike S1-CTD, Spike-RBD and Spike trimer protein.

1. SARS-CoV-2 (2019nCoV) Spike protein: SARS-CoV-2, a newly emerged pathogen spreading worldwide. The transmembrane spike (S) glycoprotein of SARS-CoV-2 that forms homotrimers protruding from the viral surface is known to mediate coronavirus entry into host cells. It has been reported that spike protein can bind with high affinity to human ACE2 and uses it as an entry receptor to invade target cells.

2. SARS-CoV-2 (2019nCoV) spike S1 protein: The spike protein is a large type I transmembrane glycoprotein comprises two functional subunits, S1 and S2. S1 subunit of spike protein is responsible for binding to the host cell receptor. S2 subunit is responsible for fusion of the viral and cellular membranes.

3. SARS-CoV-2 (2019nCoV) spike S1-NTD and S1-CTD: For most coronaviruses, the N-terminal domain (NTD) of the S1 subunit attaches to cellular carbohydrates and the C-terminal domain of S1 (S1-CTD) binds to a cellular protein receptor. Carbohydrate binding by the S1 N-terminal domain is thought to keep the virus in close proximity to the host cell surface, whereas engagement of specific protein receptors by the S1-CTD is thought to initiate a series of conformational changes in the spike that ultimately result in membrane fusion and delivery of the viral genome to the cytosol.

4. SARS-CoV-2 (2019nCoV) Spike RBD: S1 subunit of spike protein contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.

5. SARS-CoV-2 (2019nCoV) Spike trimer protein: The transmembrane spike (S) glycoprotein of SARS-CoV-2 usually forms homotrimers protruding from the viral surface. S trimers are extensively decorated with N-linked glycans that are important for proper folding and for modulating accessibility to host proteases and neutralizing Abs. It has been found that S glycoprotein trimers in highly pathogenic human coronaviruses appear to exist in partially opened states, while they remain largely closed in human coronaviruses associated with common colds.

About SARS-CoV-2 (2019nCoV, novel Coronavirus) Envelop protein (Coronavirus E protein)

1. SARS-CoV-2 (2019nCoV) E protein: E protein is the smallest major structural proteins. It has a N-terminal ectodomain and a C-terminal endodomain with ion channel activity. During the replication cycle, E protein is abundantly expressed inside the infected cell, but only a small portion is incorporated into the virus envelope. The majority of the protein participates in viral assembly and budding. E protein is important in virus production and maturation. Recombinant CoVs without E have been shown to exhibit significantly reduced viral titres, crippled viral maturation, or yield incompetent progeny.

About SARS-CoV-2 (2019nCoV, novel Coronavirus) membrane protein (Coronavirus M protein)

1. SARS-CoV-2 (2019nCoV) M protein: Coronavirus M protein is believed to define the shape of the viral envelope,which contains three transmembrane domains. It has a small N-terminal glycosylated ectodomain and a much larger C-terminal endodomain that extends 6–8 nm into the viral particle. M protein usualy exists as a dimer, and may adopt two different conformations allowing it to promote membrane curvature as well as bind to the nucleocapsid.

About SARS-CoV-2 (2019nCoV, novel Coronavirus) Nucleocapsid protein (Coronavirus N protein)

1. SARS-CoV-2 (2019nCoV) N protein: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

About SARS-CoV-2 (2019nCoV, novel Coronavirus)Non-structure protein (Nsp1-Nsp16)

2019nCoV contains 16 Non-structure protein (Nsp1-Nsp16) that may be drugable targets for antiviral compounds discovery against COVID-19¹.

1. Nsp3: Nsp3 (200 kDa) is the largest protein encoded by the coronavirus (CoV) genome. Nsp3 is an essential component of the replication and transcription complex. It comprises various domains, the organization of which differs between CoV genera, due to duplication or absence of some domains. However, the N-terminal region of the Nsp3 is highly conserved among CoV, containing a ubiquitin-like (Ubl) globular fold followed by a flexible, extended acidic-domain (AC domain) rich in glutamic acid (38%). Next to the AC domain is a catalytically active ADP-ribose-1"-phosphatase (ADRP, app-1"-pase) domain (also called macro domain or X domain) thought to play a role during synthesis of viral subgenomic RNAs. SARS Unique Domain (SUD), a domain not yet identified in other coronaviruses from alphacoronavirus and betacoronavirus, follows next. The SUD domain binds oligonucleotides known to form G-quadruplexes. Downstream of the SUD domain is a second Ubl domain and the catalytically active PLpro domain that proteolytically processes the Nsp1/2, Nsp2/3 and Nsp3/4 cleavage sites. Downstream of PLpro are found a nucleic acid-binding domain (NAB) with a nucleic acid chaperon function, which is conserved in betacoronavirus and gammacoronavirus, and one uncharacterized domain termed the marker domain (G2M). Following the G2M are two predicted double-pass transmembrane domains (TM1–2 and TM3–4), a putative metal binding region (ZN) and the Y domain of unknown function (subdomains Y1–3).

2. Nsp5: Nsp5 protease (3CLpro; Mpro) mediates processing at 11 distinct cleavage sites, including its own autoproteolysis, and is essential for virus replication. Nsp5 exhibits a conserved three-domain structure and catalytic residues.

3. Nsp10: Nsp10 (18 kDa) is well conserved among coronaviruses and encoded by ORF1a. It's thought to serve as an important multifunctional cofactor in replication. Nsp10 was shown to interact with itself, as well as with Nsp1, Nsp7, Nsp14, and Nsp16. The important role of Nsp10 is responsible for RNA synthesis. It was shown that a murine hepatitis virus (MHV) temperature-sensitive mutant carrying a non-synonymous mutation in the Nsp10 coding sequence had a defect in minus-strand RNA synthesis at non-permissive temperatures.

4. Nsp12: Nsp12 (102 kDa) is a multidomain RNA polymerase, which is the most conserved protein in coronaviruses. Nsp12 contains an RNA-dependent RNA polymerase (RdRp) domain in its C-terminal, which is essential for the viral replication and transcription.

5. Nsp16: Nsp16 is an SAM-dependent nucleoside-2’O-methyl-transferase (2’O-MTase). The mRNA cap for coronaviruses is completed by Nsp16, which ensures formation of a protective cap-1 structure that prevent recognition by either MDA5 or IFIT proteins. Finally, the NSP16/NSP10 complex finishes coronavirus capping process permitting viral infection with reduced host recognition.

About COVID-19 pandemic, Coronavirus (Coronavirus) and genome of SARS-CoV-2 (2019nCoV)

COVID-19 pandemic is caused by 2019nCoV (SARS-CoV-2, a novel coronavirus) infection.The 2019-nCoV genome was annotated to possess 14 ORFs encoding 27 proteins1.

Collection of COVID-19 landscape knowledge base

Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine - A landscape for vaccine technology against infectious disease, COVID-19 and tumor.

COVID-19 landscape Knowledge Base

An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis

Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro -- A comparison of PCR vs Immunoassay vs Crispr-Based test

References